Shares of HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) traded up 1.2% during trading on Tuesday . The stock traded as high as $0.44 and last traded at $0.41. 226,408 shares were traded during mid-day trading, a decline of 2% from the average session volume of 230,527 shares. The stock had previously closed at $0.41.
HCW Biologics Price Performance
The stock has a market cap of $15.51 million, a price-to-earnings ratio of -0.41 and a beta of 0.87. The company has a debt-to-equity ratio of 0.95, a current ratio of 0.07 and a quick ratio of 0.07. The stock’s 50 day simple moving average is $0.47 and its two-hundred day simple moving average is $0.53.
HCW Biologics Company Profile
HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
See Also
- Five stocks we like better than HCW Biologics
- What is the Nikkei 225 index?
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- How to Use the MarketBeat Dividend Calculator
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- How Investors Can Find the Best Cheap Dividend Stocks
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
